SYS-6002

NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. “We’re thrilled to welcome Dr. Nicacio to Corbus, particularly as we approach initiation of our TEMPO-1 registrational study of CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Dr. Nicacio brings a highly relevant background in solid tumor drug development and commercialization, including his pivotal role advancing the antibody drug conjugate (ADC) TIVDAK ® to market for metastatic cervical cancer. His extensive experience in ADCs as well as the HPV-driven oncology space is well matched to our strategic priorities and our continued advancement of CRB-701 for OPSCC and cervical cancer.” “I’m delighted to join Corbus at a time of notable evolution for the Company. Corbus is advancing toward multiple near-term milestones in quick succession, including CRB-701’s expected imminent entry into late-stage clinical development in 2L OPSCC, a planned readout of the CANYON-1 obesity study of CRB-913 in late summer, and an anticipated data readout of CRB-701 in 1L OPSCC in early 2027,” said Dr. Nicacio. “I’m excited to work with Yuval and the entire team as we simultaneously advance both of these novel drug candidates to address the significant unmet needs of three distinct patient populations.” Dr. Nicacio’s career spans over 20 years in the pharmaceutical industry. Prior to joining Corbus, he was the Chief Medical Officer at Protara Therapeutics, a clinical-stage company developing therapies for the treatment of cancer and rare diseases. Prior to Protara, Dr. Nicacio served as Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group, where he was responsible for establishing and executing global strategies for solid tumor development. From 2017 to 2023, he held roles of increasing responsibility at Seagen (acquired by Pfizer in December 2023), most recently as Vice President of Clinical Development, overseeing programs across a range of cancers, including bladder, breast, gynecologic, lung, colorectal, and head and neck cancers, and most notably worked on a therapeutic for metastatic cervical cancer, TIVDAK ® . Earlier in his career, Dr. Nicacio served as Senior Global Medical Lead in Global Medical Affairs at AstraZeneca, where he played an integral role in clinical, regulatory, and launch preparation activities leading up to the approval of durvalumab in bladder cancer. He also held leadership roles at Flatiron Health, where he was instrumental in building the first health technology platform focused on organizing real-world oncology data. Additionally, Dr. Nicacio held positions at Sanofi and YM Biosciences. Dr. Nicacio holds a Medical Degree from Faculdade de Ciências Médicas de Minas Gerais in Brazil and completed a molecular biology fellowship at the New York Blood Center. He is board-certified in internal medicine and medical oncology and has published extensively in top medical journals. Dr. Nicacio is an active member of the American Society of Clinical Oncology and the European Society of Medical Oncology. Corbus currently expects to initiate a registrational study of CRB-701 in 2L OPSCC (“TEMPO-1”) in the summer of 2026. Broad alignment was reached with the U.S. Food and Drug Administration (FDA) on the trial design for a randomized controlled study (n=250), which will evaluate the efficacy and safety of CRB-701 compared to investigator’s choice of monotherapy with overall response rate (ORR) as the primary endpoint for potential accelerated approval, subject to FDA review of the trial results and satisfaction of applicable regulatory requirements, and potential full approval based on overall survival (OS) benefit. Similarly, broad alignment was reached with the FDA regarding the trial design for a randomized controlled study of CRB-701 in 2L cervical cancer. In addition, Corbus currently expects to report topline findings from its CANYON-1 Phase 1b dose-ranging 16-week study (n=240) of CRB-913 as a treatment for obesity in late summer 2026. About CRB-701 CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer and highly expressed in other tumor types such as head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. About CRB-913 CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist being developed as a potential orthogonal, non-incretin approach to weight loss and long-term weight management. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on developing promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on X , LinkedIn and Facebook . Information contained on, or that can be accessed through, the Company’s website or social media channels is not incorporated by reference into this press release. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, including timing for initiation and completion of trials and presentation of data, anticipated timing for initiation of clinical trials, anticipated regulatory interactions and outcomes, including alignment with FDA on trial design and the potential sufficiency of clinical trial results to support regulatory submissions or approvals, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors relating to our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACTS : Sean Moran Chief Financial Officer Corbus Pharmaceuticals smoran@corbuspharma.com Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com MEDIA CONTACT : Liz Melone Founder & Principal Melone Communications, LLC Liz@melonecomm.com

新诺威，前身为成立于2006年的全球最大化学合成咖啡因生产商。2024年控股巨石生物后，公司正式切入创新生物药领域，目前已形成创新药、原料药及保健食品三大业务板块。公司专注于ADC、单抗及mRNA疫苗等前沿领域，已有恩朗苏拜单抗（恩舒幸）、注射用奥马珠单抗（恩益坦）等多款产品获批上市，同时依托咖啡因“现金牛”业务持续为研发输血。2026年6月，公司证券简称由“新诺威”正式变更为“石药创新”。 新诺威的2026年一季度财报中，营收6.65亿，同比增长40.82%；净利润亏损9385.47万，较上年同期亏损2,690万元进一步扩大248.88%；扣非净利润亏损1.11亿元，同比扩大262.55%。营收高增与亏损扩大的背离。 业务结构来看， 1. 传统功能性原料及保健食品仍是营收基石。一季度该业务实现收入5.06亿，同比增长35.27%。公司是全球最大化学合成咖啡因生产商，长期为可口可乐、百事可乐、Red Bull等巨头供货。但该板块近年面临增长瓶颈——2023年至2025年，传统业务收入从24.50亿元降至18.57亿元，毛利率从45.5%回落至34.7%。 2. 生物制药业务是最大亮点。一季度收入1.59亿，同比增长336.96%。其中，恩朗苏拜单抗注射液（恩舒幸）和注射用奥马珠单抗（恩益坦）商业化持续推进；更关键的是，SYS6002对外授权合作达到研发里程碑，单笔确认收入1,000万美元。这体现了创新药对外许可（BD）业务的兑现能力。 研发投入持续加码。一季度研发费用2.73亿，同比增长13.64%，研发费用率高达41%。重点布局ADC、单抗及mRNA疫苗等前沿赛道，管线推进需要大量资金投入。 一季度财务费用2079万，同比增长243.02%，主要因人民币兑美元汇率升值导致汇兑损失增加。 经营活动现金流净额-1.80亿元，投资活动现金流净额-7,093万元。公司正持续\x26quot;烧钱\x26quot;推进创新转型。 当下 ADC、海外授权行业景气，公司原料业务提供稳定现金流支撑生物药研发。与阿斯利康合作打开海外收益，多款管线进入临床关键期；短期高研发、并表拖累利润、现金流承压。若后续授权回款与新药放量兑现，有望逐步扭亏，长期具备原料药 + 创新药双成长逻辑。